SNY
SanofiAOperating peers and competitors
Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.
Loading market evidence...
Research comparisons do not establish forecast usefulness or trading returns.
Compare shared product markets
Membership only; no portfolio weights or estimated losses.
Peer overview
Useful product-specific comparator: Amgen's February 2026 filing identifies US TEZSPIRE/Dupixent competition [#REL-8673d299-bcf5-41a3-8109-9be34e57a7e0] and Repatha/Praluent competition across specified markets [#REL-833e1085-50f6-475d-aaf4-41e7f3ab427f] ([Amgen filing](https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/amgn-20251231.htm)). Neither relationship makes Amgen a whole-company valuation twin.
Grade position vs AMGN
Rotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.

